Drug recall · January 2, 2019
Temozolomide Capsules recall
Why: Failed Dissolution Specifications
Class III: unlikely to cause harm, but breaks the rules (for example a labeling error).
The recall
- Product
Temozolomide Capsules, 20 mg, packaged in a a) 5-count (NDC 43975-253-05) and b) 14 count (NDC 43975-253-14) bottles, Rx only, Mfd, by: Stason Pharmaceuticals, Inc., Irvine, CA, Dist. By: Amerigen Pharmaceuticals, Lyndhurst, NJ
- Lots / codes
a) Lot # 18B005 A and b) Lot # 18B005 B, exp 02/2020
- Quantity
- 3552 bottles
- Company
- Amerigen Pharmaceuticals Inc., Lyndhurst, NJ
- Distribution
- Product was distributed to 4 wholesalers and 2 retail accounts who may have further distributed the products.
- Initiated
- December 20, 2018 · Voluntary: Firm initiated
- Classified
- December 26, 2018
- Reported
- January 2, 2019
- Ended
- December 17, 2019
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Temozolomide
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.